Diabetes Mellitus
Pipeline by Development Stage
Drug Modality Breakdown
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 15.0yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.4yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.6yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
On Market (12)
Approved therapies currently available
Competitive Landscape
88 companies ranked by most advanced pipeline stage
+58 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 32,624 patients across 50 trials
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control
Insulin in Total Parenteral Nutrition
Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome
Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences
Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema
Inpatient Diabetes on Corticosteroids
Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy
Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes
Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics
Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients
Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees
Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir
ALPHA Sitagliptin Add on to Metformin (0431-103)
Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)
Pharmacists Management of Diabetes
LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
ASCEND: A Study of Cardiovascular Events iN Diabetes
Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
Histidine-Tryptophane-Ketoglutarate (HTK) vs University of Wisconsin (UW) Perfusion in Clinical Pancreas Transplantation
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.
IDegLira HIGH Trial
A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
Study of Combination Therapy With SYR-322
Open-label Study of TAK-875
Long-term Study of TAK-875
Long-term Study of SYR-472
BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin
Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
Related Jobs in Metabolic Diseases
Seattle Territory Business Leader
Phoenix North Territory Business Leader
Portland Clinical Diabetes Specialist
Clinical Diabetes Specialist - Tampa
Clinical Diabetes Specialist - Washington DC
Territory Business Leader - Birmingham, AL
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.